TrialDiabetes, obesity & metabolism2016

Efficacy and safety of teneligliptin, a novel dipeptidyl peptidase-4 inhibitor, in Korean patients with type 2 diabetes mellitus: a 24-week multicentre, randomized, double-blind, placebo-controlled phase III trial.

S Hong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.